AARTIDRUGS vs LUPIN: Stock Comparison

AARTI DRUGS vs LUPINUpdated 4 Sept 26, 4:08 PM ISTNSE & company filings

LUPIN is the larger company by market capitalisation. LUPIN shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

AARTIDRUGS leads 2; LUPIN leads 11 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

AARTIDRUGSLUPIN

Valuation lens

What price are you paying?

Market CapContext only
₹3,973 Cr
₹96,522 Cr
P/E RatioLUPIN has the lower reading
20x
17.79x
P/B RatioAARTIDRUGS has the lower reading
2.47x
4.38x
EPSLUPIN has the higher reading
₹5.57
₹59.37
Book ValueContext only
₹169.74
₹492.38
Dividend YieldLUPIN has the higher reading
0.46%
0.83%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
LUPIN is the larger company
₹96,522 Cr vs ₹3,973 Cr
P/E Ratio
LUPIN has a lower P/E
17.79x vs 20x
P/B Ratio
AARTIDRUGS has a lower P/B
2.47x vs 4.38x
EPS
LUPIN has higher earnings per share
₹59.37 vs ₹5.57
Dividend Yield
LUPIN has a higher dividend yield
0.83% vs 0.46%
Revenue Growth (TTM YoY)
LUPIN has faster revenue growth
31.9% vs 6.4%
EPS Growth (TTM YoY)
LUPIN has faster EPS growth
89% vs -12%
Qtr Sales Growth
AARTIDRUGS has stronger quarterly sales growth
-10.72% vs -13.35%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAARTIDRUGSLUPIN
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAARTIDRUGSLUPIN
Live Price₹431.65₹2,110
Day Change1.36%-1.03%
Volume2.5 L8.63 L
52-Week High₹534.55₹2,529.5
52-Week Low₹318.95₹1,900
Distance from 52W High-19.25%-16.58%

Valuation

MetricAARTIDRUGSLUPIN
Market Cap₹3,973 Cr₹96,522 Cr
P/E Ratio20x17.79x
P/B Ratio2.47x4.38x
EPS₹5.57₹59.37
Book Value₹169.74₹492.38
Dividend Yield0.46%0.83%

Growth

MetricAARTIDRUGSLUPIN
Revenue Growth (TTM YoY)6.4%31.9%
EPS Growth (TTM YoY)-12%89%
Qtr Sales Growth-10.72%-13.35%
Qtr Profit Growth1.44%91.58%

Profitability & Leverage

MetricAARTIDRUGSLUPIN
ROE12.05%21.13%
ROCE10.64%21.13%
Net Margin7.6%17.65%
Operating Margin9.19%40.05%
Debt to Equity0.3x0.02x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricAARTIDRUGSLUPIN
Promoter Holding54.43% 0.6 pp46.57%
FII Holding1.52% 0.06 pp22.42% 0.71 pp
DII Holding10.29% 0.07 pp24.65% 0.67 pp
Public Holding33.75% 0.57 pp6.08% 0.03 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AARTI DRUGS and LUPIN.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.